	OVER SHEET JLY
To the Honorable Com 101576750	record the attached original documents or copy thereof
1. Submission Type: 101576759	2. Conveyance Type:
■ New □ Resubmission (Non-Recordation) □ Document ID# □ Correction of PTO Error Reel # Frame # □ Corrective Document Reel # Frame # Data Element in Question :	Assignment
4. Name of conveying party(ies):	5. Name and address of receiving party(ies):
¹ Patel, Mona ² Rodgers, James D.	DUPONT PHARMACEUTICALS COMPANY CHESTNUT RUN PLAZA 974 CENTRE ROAD WILMINGTON, DELAWARE 19805
Additional name(s) of conveying party(ies) attached?: ☐ Yes ■ No Execution Date: 110/10/2000 210/10/2000	Additional name(s) & address(es) attached? Yes No
If this document is being filed together with a new application. A. Patent Application No.(s): 09/593,025 Docket No.: DM-6990-B	B. Patent No.(s):
Additional numbers	attached: ☐ Yes ■ No
6. Correspondent Name & Address: SCOTT K. LARSEN	7. Total number of applications and patents involved: 1 8. Total fee (37 CFR 3.41)
E. I. DU PONT DE NEMOURS AND COMPANY LEGAL-PATENTS 1007 MARKET STREET WILMINGTON, DELAWARE 19898	☐ Enclosed (Check No.:) ■ Authorized to be charged to deposit account
	9. Deposit account number:04-1928 (Attach duplicate copy of this page if paying by deposit account)
DO NOT US	SE THIS SPACE

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy

Signature

CAROL REEDER SENIOR LEGAL CLERK

Statement and signature.

of the original document.

09593025

00000158 041988 01/09/2001 ATHAIL

40.00 CB

Total number of pages comprising cover sheet:

Date

PATENT REEL: 011399 FRAME: 0387

PATENT APPLICATION ASSIGNMENT

We, the undersigned

Hereby declare that

We are the true and first inventors of an invention entitled SUBSTITUTED QUINOLIN-2(1H)-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS (and which is identified as Case Number DM-6990-B) and which is disclosed in an application for Letters Patent in the United States of America.

For valuable consideration, the receipt and adequacy of which is hereby acknowledged and in fulfillment of our preexisting obligation of assignment, we hereby:

- I. Sell, assign, and transfer unto DuPont Pharmaceuticals Company, a General Partnership organized and existing under the laws of the State of Delaware in the United States of America and having its principal place of business at Chestnut Run Plaza, 974 Centre Road, Wilmington, Delaware 19805, hereinafter referred to as the assignee, (A). the sole and entire right, and interest in and to: (1) the aforesaid application for Letters Patent, (2) any priority rights derived from the aforesaid application for Letters Patent by virtue of intellectual property for any and all member countries of the aforesaid International Convention or other treaty or understanding, (3) any and all of our inventions. whether joint or sole, disclosed in the aforesaid application for Letters Patent, (4) any and all applications for Letters Patent for any such inventions in any country whatsoever, (5) any and all patents for any such inventions in any country whatsoever; and (B) the sole right to (1) file such applications in its name or ours, (2) file such applications under the aforesaid International Convention or other treaty or understanding, (3) have said patents granted in its name or ours, and (4) enforce said patents and to sue for and recover profits and damages for any and all infringements thereof whether past or future; and
- II. Agree, whenever requested, to communicate to said assignee, its successors, assigns, and legal representatives, any facts known to us respecting said rights, to testify in any legal proceeding respecting said rights, to execute all applications, papers or instruments necessary or required by said assignee, its successors, assigns and legal representatives, to carry into effect any of the provisions of this instrument, and generally to do everything possible to aid said assignee, its successors, assigns, and legal representatives to obtain and enforce proper patent protection for said inventions in any and all countries.

We further authorize our attorney/patent agent to insert below* the application number and filing date of the aforesaid United States application now identified as Case Number. After the same shall have been made known to him/her by the United States Patent Office.

10th October 2000

Date: 10/10/00

James D. Ardger (L.S.)

*The application referred to above (Case No. DM-6990-B) was filed in the United States Patent

Office on June 13, 2000, and was given Application No. 09/593,025. This insertion made by me this 13 day of October

ATTORNEY/PATENT AGENT FOR APPLICANTS

PATENT REEL: 011399 FRAME: 0388

RECORDED: 12/18/2000